Table 3.
Cutaneous reactions and patient outcomes reported after COVID-19 vaccination stratified by Moderna or Pfizer manufacturer and dosinga
| Characteristic | Moderna 1st dose, n (%) | Pfizer 1st dose, n (%) | Moderna 2nd dose, n (%) | Pfizer 2nd dose, n (%) | Moderna 3rd dose, n (%) | Pfizer 3rd dose, n (%) | p valueb |
|---|---|---|---|---|---|---|---|
| Mean time to cutaneous reaction, days (SD)c | 6.5 (14.0) | 4.0 (14.6) | 5.4 (21.2) | 6.3 (20.1) | 5.1 (12.3) | 2.4 (9.2) | 0.2912 |
| Median time to cutaneous reaction, days (IQR)c | 7.0 (7.0) | 1.0 (3.0) | 1.0 (2.0) | 1.0 (3.0) | 1.0 (9.0) | 1.0 (2.0) | |
| Cutaneous reaction | |||||||
| Injection-site reactiond | 20,093 (72.50) | 2466 (28.79) | 5940 (65.54) | 2385 (36.58) | 979 (50.08) | 700 (60.34) | < 0.0001 |
| Urticaria | 6193 (22.35) | 4832 (56.42) | 2349 (25.92) | 3122 (47.88) | 872 (44.60) | 349 (30.09) | < 0.0001 |
| Papular rash | 1311 (4.73) | 527 (6.15) | 411 (4.53) | 358 (5.49) | 68 (3.48) | 48 (4.14) | < 0.0001 |
| Angioedema | 197 (0.70) | 201 (2.35) | 115 (1.27) | 133 (2.04) | 29 (1.48) | 20 (1.72) | < 0.0001 |
| Vesicular rash | 156 (0.56) | 171 (2.00) | 76 (0.84) | 142 (2.18) | 11 (0.56) | 11 (0.95) | < 0.0001 |
| Petechiae | 155 (0.56) | 180 (2.10) | 90 (0.99) | 130 (1.99) | 16 (0.82) | 16 (1.38) | < 0.0001 |
| Erythema multiforme | 96 (0.35) | 23 (0.27) | 12 (0.13) | 21 (0.32) | 5 (0.26) | 3 (0.26) | 0.0462 |
| Psoriasis | 88 (0.32) | 93 (1.09) | 63 (0.70) | 116 (1.78) | 5 (0.26) | 11 (0.95) | < 0.0001 |
| Contact dermatitis | 49 (0.18) | 54 (0.63) | 19 (0.21) | 33 (0.51) | 8 (0.41) | 6 (0.52) | < 0.0001 |
| Morbilliform rash | 40 (0.14) | 40 (0.47) | 27 (0.30) | 35 (0.54) | 5 (0.26) | 4 (0.34) | < 0.0001 |
| Pityriasis rosea | 39 (0.14) | 55 (0.64) | 39 (0.43) | 60 (0.92) | 5 (0.26) | 6 (0.52) | < 0.0001 |
| Lichen planus | 16 (0.06) | 15 (0.18) | 19 (0.21) | 31 (0.48) | 0 (0) | 2 (0.17) | < 0.0001 |
| Granuloma annulare | 15 (0.05) | 11 (0.13) | 14 (0.15) | 12 (0.18) | 0 (0) | 0 (0) | 0.0033 |
| Chilblains | 13 (0.05) | 22 (0.26) | 11 (0.12) | 7 (0.11) | 1 (0.05) | 0 (0) | < 0.0001 |
| Cutaneous vasculitis | 11 (0.04) | 10 (0.12) | 5 (0.06) | 10 (0.15) | 1 (0.05) | 1 (0.09) | 0.0200 |
| Erythromelalgia | 5 (0.02) | 5 (0.06) | 2 (0.02) | 5 (0.08) | 0 (0) | 0 (0) | 0.1018 |
| Varicella zoster virus infection | 1 (0.00) | 1 (0.01) | 0 (0) | 0 (0) | 1 (0.05) | 0 (0) | 0.1023 |
| Patient outcomes | |||||||
| Hospitalized | 211 (0.76) | 193 (2.25) | 149 (1.64) | 154 (2.36) | 17 (0.87) | 17 (1.47) | < 0.0001 |
| Disabled | 86 (0.31) | 67 (0.78) | 74 (0.82) | 66 (1.01) | 6 (0.31) | 1 (0.09) | < 0.0001 |
| Died | 5 (0.02) | 4 (0.05) | 7 (0.08) | 3 (0.05) | 0 (0) | 1 (0.09) | 0.1241 |
IQR interquartile range, SD standard deviation
aDoes not include unknown or doses >3
bBolded p values are statistically significant (p < 0.05)
cExcludes outlier cases with days to symptoms > 365 days
dErythema, pain, swelling